ADZYNMA

TAKEDA PHARMACEUTICALS AMERICA, INC.🇺🇸 United States

FDA Page

Effective Date: Aug 20, 2026
Approval ID: 22728e96-efa0-46c1-bdd1-ad89a796d5e3
Products: 2 registered
Version: 7

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use ADZYNMA safely and effectively. See full prescribing information for ADZYNMA. ADZYNMA (ADAMTS13, recombinant-krhn)lyophilized powder for Injection, for intravenous useInitial U.S. Approval: 2023

Quick Stats

Total Products2

Labelers2

Label Sections19

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.